Shopping Cart
- Remove All
Your shopping cart is currently empty
Succinobucol (Probucol monosuccinate) is a novel phenolic antioxidant small molecule with anti-oxidant and anti-inflammatory properties. It designed to treat atherosclerosis of the blood vessels of the heart or coronary artery disease.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $30 | In Stock | |
| 10 mg | $48 | In Stock | |
| 25 mg | $98 | In Stock | |
| 50 mg | $167 | In Stock | |
| 100 mg | $286 | In Stock | |
| 200 mg | $397 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $38 | In Stock |
| Description | Succinobucol (Probucol monosuccinate) is a novel phenolic antioxidant small molecule with anti-oxidant and anti-inflammatory properties. It designed to treat atherosclerosis of the blood vessels of the heart or coronary artery disease. |
| In vitro | In rabbit whole blood, Succinobucol (10, 50, 100 μM) causes a dose-dependent reduction in collagen-induced platelet aggregation. Succinobucol (10, 100 μM) significantly lowers the relaxation to X/XO. |
| In vivo | In lung metastatic breast cancer mice, Succinobucol (40 mg/kg) by tail injection significantly reduces the average number of metastatic nodules. In rats, Succinobucol (50, 100, and 150 mg/kg, i.v.) has no significant effect on either heart rate or MAP. |
| Cell Research | In the metastatic 4T1 breast cancer cells, Succinobucol, SCB and the PCD polymer (equivalent concentration to SCB) are respectively added to each well with SCB concentrations ranging from 4 ng/mL to 40 μg/mL. |
| Animal Research | Mice, injected 4T1-luc cells, are treated with Succinobucol (40 mg/kg) by tail injection every three days. |
| Synonyms | Probucol monosuccinate, AGI-1067 |
| Molecular Weight | 616.91 |
| Formula | C35H52O5S2 |
| Cas No. | 216167-82-7 |
| Smiles | CC(C)(C)c1cc(SC(C)(C)Sc2cc(c(OC(=O)CCC(O)=O)c(c2)C(C)(C)C)C(C)(C)C)cc(c1O)C(C)(C)C |
| Relative Density. | 1.13 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 45 mg/mL (72.94 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.24 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.